These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 22942311)

  • 1. Tumor necrosis factor-α inhibitor-induced antiglomerular basement membrane antibody disease in a patient with rheumatoid arthritis.
    Nishimura K; Saegusa J; Kawano S; Morinobu A
    J Rheumatol; 2012 Sep; 39(9):1904-5. PubMed ID: 22942311
    [No Abstract]   [Full Text] [Related]  

  • 2. Cerebral toxoplasmosis following adalimumab treatment in rheumatoid arthritis.
    Nardone R; Zuccoli G; Brigo F; Trinka E; Golaszewski S
    Rheumatology (Oxford); 2014 Feb; 53(2):284. PubMed ID: 24191065
    [No Abstract]   [Full Text] [Related]  

  • 3. ANCA-associated renal vasculitis following anti-tumor necrosis factor alpha therapy.
    Simms R; Kipgen D; Dahill S; Marshall D; Rodger RS
    Am J Kidney Dis; 2008 Mar; 51(3):e11-4. PubMed ID: 18295046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis.
    Stokes MB; Foster K; Markowitz GS; Ebrahimi F; Hines W; Kaufman D; Moore B; Wolde D; D'Agati VD
    Nephrol Dial Transplant; 2005 Jul; 20(7):1400-6. PubMed ID: 15840673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Graves' disease in a patient with rheumatoid arthritis during treatment with anti-tumor necrosis factor-alpha.
    van Lieshout AW; Creemers MC; Radstake TR; Elving LD; van Riel PL
    J Rheumatol; 2008 May; 35(5):938-9. PubMed ID: 18464319
    [No Abstract]   [Full Text] [Related]  

  • 7. Tumor necrosis factor-associated palmoplantar pustular psoriasis treated with interleukin 6 blocker.
    Younis S; Rimar D; Slobodin G; Rosner I
    J Rheumatol; 2012 Oct; 39(10):2055-6. PubMed ID: 23028035
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-tumor necrosis factor-alpha agents for rheumatoid arthritis: assessing longterm safety.
    Hyrich KL; Silman AJ
    J Rheumatol; 2006 May; 33(5):831-3. PubMed ID: 16652412
    [No Abstract]   [Full Text] [Related]  

  • 9. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level.
    van Rijthoven AW; Bijlsma JW; Canninga-van Dijk M; Derksen RH; van Roon JA
    Rheumatology (Oxford); 2006 Oct; 45(10):1317-9. PubMed ID: 16844698
    [No Abstract]   [Full Text] [Related]  

  • 10. Tumor necrosis factor inhibition: a part of the solution or a part of the problem of heart failure in rheumatoid arthritis?
    Gabriel SE
    Arthritis Rheum; 2008 Mar; 58(3):637-40. PubMed ID: 18311805
    [No Abstract]   [Full Text] [Related]  

  • 11. Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001).
    Ledingham J; Deighton C;
    Rheumatology (Oxford); 2005 Feb; 44(2):157-63. PubMed ID: 15637039
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-TNF-alpha therapies: they are all the same (aren't they?).
    Mpofu S; Fatima F; Moots RJ
    Rheumatology (Oxford); 2005 Mar; 44(3):271-3. PubMed ID: 15561736
    [No Abstract]   [Full Text] [Related]  

  • 13. Dermatomyositis in patients with rheumatoid arthritis during adalimumab therapy.
    Nagashima T; Minota S
    J Rheumatol; 2011 Mar; 38(3):574; author reply 575. PubMed ID: 21362792
    [No Abstract]   [Full Text] [Related]  

  • 14. Pseudolymphomatoid cutaneous leishmaniasis in a patient treated with adalimumab for rheumatoid arthritis.
    Baltà-Cruz S; Alsina-Glbert M; Mozos-Rocafort A; Cervera C; Colomo-Saperas L; Del Río A; Estrach-Panella T
    Acta Derm Venereol; 2009; 89(4):432-3. PubMed ID: 19688168
    [No Abstract]   [Full Text] [Related]  

  • 15. New drugs for rheumatoid arthritis.
    Olsen NJ; Stein CM
    N Engl J Med; 2004 May; 350(21):2167-79. PubMed ID: 15152062
    [No Abstract]   [Full Text] [Related]  

  • 16. Unstable diabetes in a patient receiving anti-TNF-alpha for rheumatoid arthritis.
    Boulton JG; Bourne JT
    Rheumatology (Oxford); 2007 Jan; 46(1):178-9. PubMed ID: 16998233
    [No Abstract]   [Full Text] [Related]  

  • 17. Sarcoidosis during anti-tumor necrosis factor-alpha therapy: no relapse after rechallenge.
    van der Stoep D; Braunstahl GJ; van Zeben J; Wouters J
    J Rheumatol; 2009 Dec; 36(12):2847-8. PubMed ID: 19966199
    [No Abstract]   [Full Text] [Related]  

  • 18. [Adalimumab induced-inflammatory myopathy in rheumatoid arthritis].
    de Souza FH; Barros TB; Levy-Neto M; Shinjo SK
    Acta Reumatol Port; 2012; 37(2):180-3. PubMed ID: 23149641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How FABulous is PEGgy? Certoliziumab pegol from the bench to the patients.
    Aletaha D
    BioDrugs; 2014 Apr; 28 Suppl 1():S3-4. PubMed ID: 24687233
    [No Abstract]   [Full Text] [Related]  

  • 20. Alopecia areata universalis during treatment of rheumatoid arthritis with anti-TNF-alpha antibody (adalimumab).
    Chaves Y; Duarte G; Ben-Said B; Tebib J; Berard F; Nicolas JF
    Dermatology; 2008; 217(4):380. PubMed ID: 18849606
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.